DP2

Helix Announces Decommissioning Contract Extension with Trident Energy and other Commercial Updates

Retrieved on: 
Tuesday, February 6, 2024
Robotics, Other Energy, Maritime, Technology, Transport, Alternative Energy, Energy, Trident, SLB, HLX, Remotely operated underwater vehicle, Green Canyon, Campos Basin, HPI, Helix, Siem, DP2, Hydrocarbon, Helix Energy Solutions Group, ROV

Helix Energy Solutions Group, Inc. (NYSE: HLX) is pleased to announce the extension of its decommissioning contract with Trident Energy do Brasil Ltda.

Key Points: 
  • Helix Energy Solutions Group, Inc. (NYSE: HLX) is pleased to announce the extension of its decommissioning contract with Trident Energy do Brasil Ltda.
  • The contract extension is for an additional 12 months and in direct continuation of the current contract.
  • The extension is expected to begin in the fourth quarter of 2024 at rates in line with the improved well intervention market.
  • Helix and Siem Offshore have signed six-year charter extensions for both the Siem Helix vessels, with the Siem Helix 1 term extending through December 2030 and the Siem Helix 2 term extending through December 2031.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, September 19, 2023
TNBC, CRISPR, PBCC, Cell biology, University, Molecule, Nature Cancer, ACSS2, Culture, Genomics, DP2, HER2, Wistar, Breast, Infection, HIC, Cancer, Biomedical Research, Immunity, Jim Valvano, Research, Zhug, Bangladesh Technical Education Board, Ellen, National Cancer Institute, Triple-negative breast cancer, Patient, Metabolism, Wistar Institute, Immune system, University of Bologna, NCI, P30, NIH, Breast cancer, Vaccine

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points: 
  • Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
  • Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
  • The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
  • TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.

Ten Ltd. Reports Profits for the Second Quarter and Six Months Ended June 30, 2023 and Declares Total Annual Dividend of $1.00 Per Common Share for 2023

Retrieved on: 
Thursday, September 7, 2023
Interest, TCE, DP2, Sale, LNG, EBITDA, Acquisition, Depreciation, TNP, TEN, Transport, VLCC, NYSE, Rare-earth element, Shipbuilding, Clothing, Video game, Security (finance), Holding company

Adjusted Earnings Before Interest Tax Depreciation & Amortization (EBITDA) more than doubled to $275.2 million from $133.3 million in the 2022 first six months, a 107% increase.

Key Points: 
  • Adjusted Earnings Before Interest Tax Depreciation & Amortization (EBITDA) more than doubled to $275.2 million from $133.3 million in the 2022 first six months, a 107% increase.
  • Adjusted EBITDA for the second quarter of 2023 recorded a 32% increase from the 2022 equivalent period and settled at $120.2 million.
  • Fleet utilization, despite a number of scheduled dry-dockings, remained high at 94.2% compared to 93.6% in the second quarter of 2022.
  • Payment for the special dividend is scheduled for October 26, 2023, to shareholders of record on October 20, 2023.

Wintermar Offshore (WINS:JK) Reports 1H2023 Results

Retrieved on: 
Monday, July 31, 2023
Maintenance, OSV, IEA, Dynamic positioning, DP2, WINS, International Energy Agency, AHTS, Platform supply vessel, YOY, EBITDA, Investment, SE, Yoy, PSV, Airline, Shipbuilding, Insurance, Construction, Southeast Asia, Q3

JAKARTA, July 31, 2023 - (ACN Newswire) - PT Wintermar Offshore Marine Tbk (WINS:JK) has announced results for 1H2023.

Key Points: 
  • JAKARTA, July 31, 2023 - (ACN Newswire) - PT Wintermar Offshore Marine Tbk (WINS:JK) has announced results for 1H2023.
  • This was achieved as a result of securing higher charter rates, in spite of a decrease in fleet utilization from 66% in 1H2022 to 61% in 1H2023.
  • Bunker costs also rose by 23% to US$1.3 million due to a higher number of vessels being out of contract.
  • Wintermar expects a stronger performance throughout the remainder of the year, driven by the successful award of several contracts for high-tier vessels.

TEN Ltd. Reports Record Profits for Fourth Quarter and Year-End 2022 and Declares Annual Dividend of $0.60 Per Common Share

Retrieved on: 
Thursday, March 16, 2023
Acquisition, TNP, Sale, International, Webcast, NYSE, TEN, Depreciation, COVID-19, ATM, Handysize, EBITDA, VLCC, Growth, DP2, TCE, Interest, Cryptocurrency, Renewable energy, Semiconductor, Bank, Shipbuilding, Video game, Security (finance), Broadcasting, LNG, Suezmax

There were no material non-cash impairment charges in 2022, unlike 2021 where such charges amounted to $86.4 million.

Key Points: 
  • There were no material non-cash impairment charges in 2022, unlike 2021 where such charges amounted to $86.4 million.
  • In the 2022 fourth quarter, with essentially the same number of vessels as the 2021 fourth quarter, TEN generated voyage revenues of $270 million, almost doubling the revenues generated in the 2021 fourth quarter.
  • Net income attributable to TEN in the fourth quarter of 2022 amounted to $101.1 million, or $3.17 per share, the company’s best quarter since its inception in 1993.
  • During the fourth quarter of 2022, the Company issued 569,207 common shares through its ATM program for net proceeds of $10.4 million.

Wintermar Offshore (WINS:JK) Acquires 2 Additional AHTS and Celebrates the 12th Anniversary of Listing on IDX

Retrieved on: 
Wednesday, November 30, 2022
Platform supply vessel, Growth, Quality, Stanza, Environment, DP2, OSV, WINS, Occupational safety and health, ISO 9001:2015, Asset integrity management systems, IDX, DP1, AHTS, ISO, ABS, PSV, IPO

The two AHTS will be delivered by December 2022, are ABS classed and have DP1 and FiFi1 capability, and expected to be utilized from 1Q2023.

Key Points: 
  • The two AHTS will be delivered by December 2022, are ABS classed and have DP1 and FiFi1 capability, and expected to be utilized from 1Q2023.
  • With this latest purchase, Wintermar's fleet will be increased the fleet to 41 Vessels by end December 2022.
  • Today also marks the Company's 12th IPO anniversary, as Wintermar's shares were first listed on the IDX on November 29, 2010.
  • All vessels are operated by experienced Indonesian crew, tracked by satellite systems and monitored in real-time by shore-based Vessel Teams.

TEN Ltd Reports Strong Results for the Third Quarter and Nine Months Ended September 30, 2022

Retrieved on: 
Tuesday, November 22, 2022
Environment, DP2, Depreciation, EBITDA, ESG, TEN, Social, Policy, TCE, VLCC, Webcast, NYSE, COVID-19, TNP, Holding company, Video game, Renewable energy, Shipbuilding, Real estate, Oil, Broadcasting, LNG

Total payments of $500 million since 2002

Key Points: 
  • Total payments of $500 million since 2002
    ATHENS, Greece, Nov. 22, 2022 (GLOBE NEWSWIRE) -- TEN, Ltd (TEN) (NYSE: TNP) (the Company) today reported results (unaudited) for the nine months and third quarter ended September 30, 2022.
  • Net income for the first nine months of 2022 exceeded $103 million or $2.77 per share.
  • Adjusted EBITDA reached $236 million in the 2022 first nine months, $150 million higher than the 2021 nine-month level.
  • Adjusted EBITDA amounted to $103 million in the 2022 third quarter, over five times higher than the 2021 third quarter.

Helix Energy Solutions Announces Contract Extension with Talos for Helix Producer I

Retrieved on: 
Tuesday, November 22, 2022
Maritime, Other Energy, Transport, Oil, Gas, Alternative Energy, Energy, Helix Energy Solutions Group, Gulf of Mexico, ESG, Helix Producer 1, Energy transition, DTS, Hydrocarbon, NYSE, Weather, TALO, Acquisition, Security (finance), Robotics, Annual report, Helix, HLX, DP2, COVID-19, Risk management, Phoenix, Talos

Helix Energy Solutions Group, Inc. (NYSE: HLX) announced today that an affiliate of Talos Energy Inc. (Talos) (NYSE:TALO) has extended for one year the term of its contract with Helix for the Helix Producer I floating production vessel in the Gulf of Mexico.

Key Points: 
  • Helix Energy Solutions Group, Inc. (NYSE: HLX) announced today that an affiliate of Talos Energy Inc. (Talos) (NYSE:TALO) has extended for one year the term of its contract with Helix for the Helix Producer I floating production vessel in the Gulf of Mexico.
  • The one-year extension term is scheduled to conclude on June 1, 2024 with Talos having the option to extend the contract annually.
  • Scotty Sparks, Helixs Executive Vice President and Chief Operating Officer, stated, We are pleased to extend our contract on the Helix Producer I and look forward to continuing our long-term working relationship with Talos.
  • The Helix Producer I is a unique vessel that has provided safe and reliable production processing for Talos, and this extension further demonstrates our ability to continue meeting our clients needs.

COVID-19 Virus Increases Risk for Other Infections by Disrupting Normal Mix of Gut Bacteria

Retrieved on: 
Tuesday, November 1, 2022
MPH, Hospital, Research, Infection, COVID-19, Department, Coronavirus, NYU Langone Health, National Institutes of Health, Howard Hughes Medical Institute, Man, Severe acute respiratory syndrome coronavirus 2, Schluter, Jan, Crohn's disease, Immune system, G.H. Raisoni Department of Microbiology and Biotechnology, Book of Judith, Jan Vilček, Vedanta, Cadwell, Nature Communications, Patient, New York University Grossman School of Medicine, Yale University, The Kenneth Rainin Foundation, Genetics, Risk, Physician, Bacteria, Disease, Woman, Yale School of Public Health, National, Crohn's & Colitis Foundation, Q-system (genetics), Yale school, AbbVie, Mouse, NYU, DP2, Public health, Vaccine, Antibiotics, Pharmaceutical industry, Dietary supplement, MD, Autoimmunity, Doctor of Philosophy, Medicine, Microbiology

However, researchers say, it has remained unclear until now which came first, the coronavirus infection disrupting the gut microbiome or an already weakened gut making the body more vulnerable to the virus.

Key Points: 
  • However, researchers say, it has remained unclear until now which came first, the coronavirus infection disrupting the gut microbiome or an already weakened gut making the body more vulnerable to the virus.
  • The new investigation also revealed that antibiotic-resistant species can escape into the bloodstream, putting patients at greater risk for life-threatening secondary infections.
  • These antibiotic-resistant bacteria found in the gut were also observed to have migrated into the bloodstream in 20% of patients.
  • If any bacteria group made up a majority of the bacteria living in the gut, they were considered dominant.

WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA

Retrieved on: 
Tuesday, September 20, 2022
Development, ESG, DS, FDA, Food, European Medicines Agency, PAI, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Approved Drug Products with Therapeutic Equivalence Evaluations, Solution, Biophysical environment, DP, WuXi Biologics, Contract research organization, GMP, EMA, DP2, Pharmaceutical industry, Medical device, Fine chemical, Social

WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Key Points: 
  • WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
  • After passing online Pre-Approval Inspection (PAI), WuXi Biologics received EMA GMP certificates for the commercial manufacturing of two biologics developed by global clients at its MFG4, MFG5 and DP2 facilities.
  • The U.S. FDA also approved MFG5 to manufacture an innovative product for a global client.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We're proud that our additional DS and DP facilities have again been approved by both the U.S. FDA and EMA.